These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 26018927)

  • 1. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.
    Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM
    Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node transfer and perinodal lymphatic growth factor treatment for lymphedema.
    Honkonen KM; Visuri MT; Tervala TV; Halonen PJ; Koivisto M; Lähteenvuo MT; Alitalo KK; Ylä-Herttuala S; Saaristo AM
    Ann Surg; 2013 May; 257(5):961-7. PubMed ID: 23013803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth factor therapy and lymph node graft for lymphedema.
    Tervala TV; Hartiala P; Tammela T; Visuri MT; Ylä-Herttuala S; Alitalo K; Saarikko AM
    J Surg Res; 2015 Jun; 196(1):200-7. PubMed ID: 25777822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphangiogenic growth factors, receptors and therapies.
    Lohela M; Saaristo A; Veikkola T; Alitalo K
    Thromb Haemost; 2003 Aug; 90(2):167-84. PubMed ID: 12888864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
    Lohela M; Heloterä H; Haiko P; Dumont DJ; Alitalo K
    Am J Pathol; 2008 Dec; 173(6):1891-901. PubMed ID: 18988807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
    Rissanen TT; Markkanen JE; Gruchala M; Heikura T; Puranen A; Kettunen MI; Kholová I; Kauppinen RA; Achen MG; Stacker SA; Alitalo K; Ylä-Herttuala S
    Circ Res; 2003 May; 92(10):1098-106. PubMed ID: 12714562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of Vascular Endothelial Growth Factor-C156S in Therapeutic Lymphangiogenesis: A Systematic Review.
    Forte AJ; Boczar D; Huayllani MT; Anastasiadis PZ; McLaughlin S
    Lymphat Res Biol; 2022 Dec; 20(6):580-584. PubMed ID: 35501971
    [No Abstract]   [Full Text] [Related]  

  • 9. Extracorporeal shock wave therapy combined with vascular endothelial growth factor-C hydrogel for lymphangiogenesis.
    Kim IG; Lee JY; Lee DS; Kwon JY; Hwang JH
    J Vasc Res; 2013; 50(2):124-33. PubMed ID: 23208012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphangiogenic gene therapy with minimal blood vascular side effects.
    Saaristo A; Veikkola T; Tammela T; Enholm B; Karkkainen MJ; Pajusola K; Bueler H; Ylä-Herttuala S; Alitalo K
    J Exp Med; 2002 Sep; 196(6):719-30. PubMed ID: 12235206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
    Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
    Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular control of lymphatic metastasis.
    Achen MG; Stacker SA
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1.
    Jha SK; Rauniyar K; Karpanen T; Leppänen VM; Brouillard P; Vikkula M; Alitalo K; Jeltsch M
    Sci Rep; 2017 Jul; 7(1):4916. PubMed ID: 28687807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
    Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
    Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.
    Karkkainen MJ; Haiko P; Sainio K; Partanen J; Taipale J; Petrova TV; Jeltsch M; Jackson DG; Talikka M; Rauvala H; Betsholtz C; Alitalo K
    Nat Immunol; 2004 Jan; 5(1):74-80. PubMed ID: 14634646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S.
    Bhansali SG; Balu-Iyer SV; Morris ME
    J Pharm Sci; 2012 Feb; 101(2):852-9. PubMed ID: 22030745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins.
    Tammela T; He Y; Lyytikkä J; Jeltsch M; Markkanen J; Pajusola K; Ylä-Herttuala S; Alitalo K
    Circ Res; 2007 May; 100(10):1468-75. PubMed ID: 17478733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation.
    Karpanen T; Wirzenius M; Mäkinen T; Veikkola T; Haisma HJ; Achen MG; Stacker SA; Pytowski B; Ylä-Herttuala S; Alitalo K
    Am J Pathol; 2006 Aug; 169(2):708-18. PubMed ID: 16877368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.